A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of a Titrating-Dose Lonafarnib in Combination With Ritonavir in Patients Chronically Infected With Hepatitis Delta Virus

Trial Profile

A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of a Titrating-Dose Lonafarnib in Combination With Ritonavir in Patients Chronically Infected With Hepatitis Delta Virus

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Lonafarnib (Primary) ; Ritonavir
  • Indications Hepatitis D
  • Focus Adverse reactions
  • Acronyms LOWR HDV - 4; LOWR-4
  • Sponsors Eiger BioPharmaceuticals
  • Most Recent Events

    • 21 Apr 2017 Results from the LOWER HDV program published in an Eiger BioPharmaceuticals, Inc. media release.
    • 21 Apr 2017 According to an Eiger BioPharmaceuticals, Inc. media release, data from the study has been presented at the The International Liver Congress 2017.
    • 06 Apr 2017 According to an Eiger BioPharmaceuticals, Inc. media release, data from the study will be presented at the European Association for the Study of the Liver (EASL) meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top